Plaquenil (Hydroxychloroquine): Clinical Guide
Indications
Plaquenil is FDA-approved for malaria prophylaxis and treatment, lupus erythematosus, and rheumatoid arthritis 1. Beyond these core indications, HCQ demonstrates efficacy in primary Sjögren syndrome, cutaneous manifestations of rheumatic diseases, dermatomyositis, porphyria cutanea tarda, and cutaneous sarcoidosis 2, 3. The drug provides substantial mortality benefit in systemic lupus erythematosus patients and reduces disease activity, organ damage, and pregnancy-related complications 2.
Dosing Guidelines
The critical dosing threshold is ≤5.0 mg/kg/day based on actual body weight, not ideal body weight 4, 5. This represents a major shift from older recommendations that used ≤6.5 mg/kg/day.
Specific Dosing by Indication:
Lupus Erythematosus: 200-400 mg daily (single or divided doses). Do not exceed 400 mg/day 1
Rheumatoid Arthritis:
- Initial: 400-600 mg daily
- Maintenance: 200-400 mg daily after therapeutic response achieved
- Maximum: 600 mg/day or 6.5 mg/kg/day, whichever is lower 1
Malaria Prophylaxis: 400 mg weekly (or 6.5 mg/kg, not exceeding 400 mg) 1
For severely obese patients, keep the dose under 400 mg/day regardless of weight-based calculations 5. The evidence shows that doses ≤5.0 mg/kg provide <2% risk of toxicity within 10 years, while higher doses increase retinopathy risk to ~10% after 10 years 4.
Monitoring Requirements
Baseline Examination (Within First Year)
All patients require a baseline ophthalmologic examination including 4, 5:
- Best corrected distance visual acuity (BCVA)
- Automated threshold visual field testing of central 10 degrees (24 degrees for Asian patients)
- Spectral domain optical coherence tomography (SD-OCT)
- Wide-pattern fundus autofluorescence (FAF)
Ongoing Screening
Annual ophthalmologic screening should begin after 5 years of treatment for patients without significant risk factors 4, 5.
For high-risk patients, annual screening should begin after 1 year 4, 5. High-risk factors include:
- Daily dose >5.0 mg/kg actual body weight
- Subnormal glomerular filtration/renal disease
- Concurrent tamoxifen use
- Pre-existing macular disease
- Older age at HCQ initiation
Primary screening tools are OCT and FAF; visual fields and multifocal ERG serve as confirmatory tests 5. The 24-2C visual field algorithm can screen both parafoveal and pericentral regions simultaneously 5.
Critical Monitoring Caveat
Asian patients require wider visual field testing (central 24 degrees instead of 10 degrees) because they typically develop pericentral rather than parafoveal toxicity patterns 4, 6, 5. However, both patterns can occur in any ethnicity, so screening should assess both regions 5.
Contraindications and Warnings
Absolute Concerns:
- Chloroquine-resistant P. falciparum malaria (drug is ineffective) 1
- Known retinal or visual field changes from prior antimalarial use 1
Serious Warnings Requiring Careful Risk-Benefit Assessment:
Cardiac toxicity: Life-threatening and fatal cardiomyopathy reported, presenting as atrioventricular block, pulmonary hypertension, sick sinus syndrome, or bundle branch blocks. Clinical monitoring with ECG is advised. Discontinue immediately if cardiotoxicity suspected 1.
QT prolongation: Ventricular arrhythmias and torsades de pointes reported. Do not combine with other QT-prolonging drugs 1.
Psoriasis and porphyria: May precipitate severe attacks. Use only if benefits clearly outweigh risks 1.
Proximal myopathy/neuropathy: Progressive weakness, atrophy, depressed reflexes can occur. Monitor for muscle weakness 1.
When to Stop Therapy
Discontinue immediately if:
- Ocular toxicity detected on screening (though mild retinopathy may warrant discussion rather than automatic cessation) 4
- Signs of cardiomyopathy or conduction abnormalities 1
- Severe muscle weakness or neuropathy develops 1
Important: Retinal changes may progress even after drug cessation, particularly in severe cases. Mild retinopathy is unlikely to progress after stopping 5. This creates a clinical dilemma requiring shared decision-making with patients about continuing therapy with close monitoring versus stopping for borderline findings 4.
Alternative Therapies
When HCQ cannot be used or fails:
For lupus: Immunosuppressants (methotrexate, azathioprine, mycophenolate), biologics (belimumab), glucocorticoids (though HCQ reduces steroid requirements) 2
For rheumatoid arthritis: Methotrexate, other DMARDs, biologics (TNF inhibitors, IL-6 inhibitors), JAK inhibitors 1
For dermatologic conditions: Quinacrine can be combined with HCQ for increased effectiveness, or used as alternative. Dapsone, systemic corticosteroids, immunosuppressants depending on specific condition 3
Combination therapy: HCQ works synergistically with corticosteroids and allows dose reduction of steroids, reducing their side effects 1, 3. This makes HCQ particularly valuable as part of combination regimens rather than as monotherapy.
Key Clinical Pearls
HCQ is a valuable, generally safe medication that should not be avoided due to fear of retinopathy when dosed correctly and monitored appropriately 4. The goal is to maintain patients on this beneficial drug as long as safely possible, not to stop it casually for borderline findings 4.
Take with food or milk to reduce gastrointestinal side effects 1.
Therapeutic effects are cumulative, requiring weeks to months to achieve maximum benefit in rheumatic diseases 1. Patients need counseling about delayed onset of action.
The retina typically remains normal for years before unpredictable onset of toxicity 5. Even after 20 years of use, annual risk of developing retinopathy remains <5% if the prior year's screening was normal 4.